‘Sle Market Worth Over $570 Million In 2017’ Says Visiongain Report

21 August 2017
Pharma

Visiongain’s new report The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography indicates that the SLE market will see over $570m in revenue in 2017.
The lead analyst of the report said:

“Systemic Lupus Erythematosus (SLE) is an autoimmune disease as the body's immune system mistakenly attacks healthy tissue. It affects the skin, joints, kidneys, brain, and other organs. Systemic Lupus Erythematosus is a chronic disease characterized with phases of worsening symptoms that alternate with periods of mild symptoms. Most people with Systemic Lupus Erythematosus lead a normal life with treatment. The term lupus used to identify a number of immune diseases that have homogenous clinical presentations and laboratory features, however Systemic Lupus Erythematosus is the most common type of lupus.

Currently, a lot of research activity is going on in the field of Systemic Lupus Erythematosus. There are around 60 molecules in active pipeline development. Many new therapies and mechanism of action are being tested in the pre-clinical stages or early stages like BTK, JAK inhibitors and T-cell modulator etc.

The current growth in Systemic Lupus Erythematosus market has also been fuelled by the therapies based on oral route of delivery. The diseases providing a greater benefit also commands a relatively higher price in the rare disease space.

The 152-page report contains 114 tables, charts and graphs that add visual analysis in order to explain developing trends within the Systemic Lupus Erythematosus market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading SLE submarkets, segmented by product, including forecasts for Atacicept, Benlysta, Anifrolumab, Lulizumab, Bisibimod, CellCept and Prograf. The SLE market is also segmented by Molecule Type, with forecasts for Small Molecules, Monoclonal Antibodies and Recombinant Proteins. The market is also segmented by pharmacological class, with forecasts for B-Cell Targeting Therapies, Interferon Receptor Antagonists, CD Antagonist Therapies and other Therapies for SLE.

The 152-page report offers market forecasts and analysis for 2 regional and 9 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 6 companies leading the SLE field in detail.

The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography report will be of value to anyone who wants to better understand the SLE market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the systemic lupus erythematosus therapy industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever